New Generation Technologies

Ark Surgical is a medical device start-up focused on enhancing laparoscopic surgery through innovative solutions. The company has developed LapBox, a containment system designed to safely remove large internal organs via a laparoscopic keyhole incision. This device significantly reduces the risk of cancerous tissue dispersion during minimally invasive procedures, particularly in women's health. The first version of LapBox has received FDA clearance, with a second iteration in development. By enabling surgeons to perform safe organ removals without the complications associated with traditional tissue morcellation, Ark Surgical aims to improve patient outcomes in laparoscopic surgeries.

Bankin' is the Best Mobile Money Manager. Bankin' app makes money management super easy. At Bankin', they believe that money management must be simple, transparent and efficient so you can focus on what really matters to you. Their mission is to bring innovation and technology together to offer you the best solution to guide you every day. They are the leader in Europe: you are more than 1.5 million to trust us in France, in England, in Spain, and in Germany. They are the only company independent of banks in Europe. It is something they feel very strongly about because it allows us to provide better guidance by always suggesting what's right for you.

CartiCure is a MedTech company in the domain of tissue engineering; developing innovating technology for cartilage defects repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.